American Journal of Kidney Diseases
Volume 55, Issue 5 , Pages 813-816 , May 2010

Urinary Tubular Biomarkers of Kidney Damage: Potential Value in Clinical Practice

  • Femke Waanders, MD, PhD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Femke Waanders, MD, PhD, University Medical Center Groningen, Kidney Center, PO Box 30.001, 9700 RB Groningen, The Netherlands
    • ,
  • Gerjan Navis, MD, PhD
    • ,
  • Harry van Goor, PhD

References 

  1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047
  2. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–1559
  3. Hamming I, Navis G, Kocks MJ, van Goor H. ACE inhibition has adverse renal effects during dietary sodium restriction in proteinuric and healthy rats. J Pathol. 2006;209:129–139
  4. Kramer AB, Laverman GD, van Goor H, Navis G. Inter-individual differences in anti-proteinuric response to ACEi in established Adriamycin nephrotic rats are predicted by pretreatment renal damage. J Pathol. 2003;201:160–167
  5. Wehrmann M, Bohle A, Bogenschutz O, et al. Long-term prognosis of chronic idiopathic membranous glomerulonephritis (An analysis of 334 cases with particular regard to tubulo-interstitial changes). Clin Nephrol. 1989;31:67–76
  6. Perico N, Cattaneo D, Remuzzi G. Kidney injury molecule 1: in search of biomarkers of chronic tubulointerstitial damage and disease progression. Am J Kidney Dis. 2009;53:1–4
  7. Kern EO, Erhard P, Sun W, Genuth S, Weiss MF. Early urinary markers of diabetic kidney disease: a nested case-control study from the Diabetes Control and Complications Trial (DCCT). Am J Kidney Dis. 2010;55(5):824–834
  8. Bazzi C, Petrini C, Rizza V, Arrigo G, Beltrame A, D'Amico G. Characterization of proteinuria in primary glomerulonephritides (SDS-PAGE patterns: clinical significance and prognostic value of low molecular weight (“tubular”) proteins). Am J Kidney Dis. 1997;29:27–35
  9. Waanders F, van Timmeren MM, Stegeman CA, Bakker SJ, van Goor H. Kidney injury molecule-1 in renal disease. J Pathol. 2010;220:7–16
  10. van Timmeren MM, van den Heuvel MC, Bailly V, Bakker SJ, Van GH, Stegeman CA. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol. 2007;212:209–217
  11. Waanders F, Vaidya VS, van Goor H, et al. Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial. Am J Kidney Dis. 2009;53:16–25
  12. Ichimura T, Asseldonk EJ, Humphreys BD, Gunaratnam L, Duffield JS, Bonventre JV. Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Invest. 2008;118:1657–1668
  13. Bolignano D, Lacquaniti A, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:337–344
  14. Kuwabara T, Mori K, Mukoyama M, et al. Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney Int. 2009;75:285–294
  15. Bazzi C, Petrini C, Rizza V, et al. Urinary N-acetyl-beta-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis. Nephrol Dial Transplant. 2002;17:1890–1896
  16. Heidland A, Sebekova K, Schinzel R. Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis. 2001;38(4 suppl 1):S100–S106
  17. Waanders F, Greven WL, Baynes JW, et al. Renal accumulation of pentosidine in non-diabetic proteinuria-induced renal damage in rats. Nephrol Dial Transplant. 2005;20:2060–2070
  18. Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol. 2007;27:605–614
  19. Tam FW, Riser BL, Meeran K, Rambow J, Pusey CD, Frankel AH. Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy. Cytokine. 2009;47:37–42
  20. Andersen S, van Nieuwenhoven FA, Tarnow L, et al. Reduction of urinary connective tissue growth factor by losartan in type 1 patients with diabetic nephropathy. Kidney Int. 2005;67:2325–2329
  21. Houlihan CA, Akdeniz A, Tsalamandris C, Cooper ME, Jerums G, Gilbert RE. Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. Diabetes Care. 2002;25:1072–1077
  22. Kottgen A, Hwang SJ, Larson MG, et al. Uromodulin levels associate with a common UMOD variant and risk for incident CKD. J Am Soc Nephrol. 2010;21(2):337–344
  23. Damman K, van Veldhuisen DJ, Navis G, et al. Tubular damage is common and associated with reduced survival in patients with chronic heart failure [abstract]. J Am Coll Cardiol. 2009;53(10):A162
  24. Han WK, Wagener G, Zhu Y, Wang S, Lee HT. Urinary biomarkers in the early detection of acute kidney injury after cardiac surgery. Clin J Am Soc Nephrol. 2009;4:873–882

PII: S0272-6386(10)00122-8

doi: 10.1053/j.ajkd.2010.02.002

American Journal of Kidney Diseases
Volume 55, Issue 5 , Pages 813-816 , May 2010

Article Tools

* Image Usage & Resolution